On the other hand, the expression levels of Pmp22 in BBN-induced bladder cancer group were significantly decreased as compared with normal or BBN + nicotinamide-treated groups (P = 0.02 and P = 0.03 by two sample t-test respectively, Figure 4, B). This evidence concerns the gene PMP22 and urinary bladder carcinoma.